Royalty Pharma Plc (RPRX) live share price

Royalty Pharma Plc share price in USD $26.66 & INR ₹2,257.97

$26.66

▲

0.06

(0.23%)

View live Royalty Pharma Plc share price in Dollar and Rupees. Guide to invest in Royalty Pharma Plc from India. Also see the sentimental analysis on Indian investors investing in Royalty Pharma Plc. Get details on the Indian mutual funds that are investing in Royalty Pharma Plc. Get Analyst recommendations and forecasts along with all the Royalty Pharma Plc's financials.

Royalty Pharma Plc share price movements

$26.46
$27.00
$26.66
0.75%
Downside
Day's Volatility :2.0%
Upside
1.26%
$25.10
$31.66
$26.66
5.85%
Downside
52 Weeks Volatility :20.71%
Upside
15.78%

Royalty Pharma Plc Returns

Period	Royalty Pharma Plc	Sector (Health Care)	Index (Russel 2000)
3 Months	-7.69%	-6.2%	0.0%
6 Months	-0.67%	2.6%	0.0%
1 Year	-5.86%	11.8%	0.0%
3 Years	-29.19%	13.3%	-19.8%

Royalty Pharma Plc Key Statistics

in dollars & INR

Market Capitalization	$15.7B
Revenue TTM	$2.3B
EBITDA	$1.5B
Earnings Per Share (EPS)	$2.54
PE Ratio	10.47
Dividend Yield	3.16%
Profit Margin	50.53%
Quarterly Earnings Growth YOY	6.59%
Return On Equity TTM	17.28%

How to invest in Royalty Pharma Plc from India?

It is very easy for Indian residents to invest directly in Royalty Pharma Plc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Royalty Pharma Plc stock in both rupees (INR) and dollars (USD). Search for Royalty Pharma Plc or RPRX on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Royalty Pharma Plc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Royalty Pharma Plc shares which would translate to 0.032 fractional shares of Royalty Pharma Plc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Royalty Pharma Plc

214%

Period: Sep 2, 2024 to Dec 1, 2024. Change in 30 Days versus previous period

Search volume for Royalty Pharma Plc on INDmoney from India has grown in the last 30 days as on Dec 2, 2024. 214% more investors are searching Royalty Pharma Plc in the last 30 days versus the previous period.

Global Institutional Holdings in Royalty Pharma Plc

Morgan Stanley - Brokerage Accounts
19.79%
Vanguard Group Inc
8.43%
FMR Inc
6.25%
BlackRock Inc
5.16%
Baillie Gifford & Co Limited.
3.61%
Viking Global Investors LP
2.71%

Analyst Recommendation on Royalty Pharma Plc

Buy

85%Buy

14%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Royalty Pharma Plc(by analysts ranked 0 to 5 stars)

Based on 14 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Royalty Pharma Plc

What analysts predicted

Upside of 55.77%

Current:

$26.66

Target:

$41.53

Insights on Royalty Pharma Plc

Increasing Revenue
Revenue is up for the last 2 quarters, 537.26M → 564.69M (in $), with an average increase of 4.9% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, 4.77M → 543.98M (in $), with an average increase of 88.3% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 47.6% return, outperforming this stock by 50.1%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 38.4% return, outperforming this stock by 69.8%

Royalty Pharma Plc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$1.8B	↑ 12.33%
Net Income	$1.4B	↑ 13.86%
Net Profit Margin	76.76%	↑ 1.04%

	FY19	Y/Y Change
Revenue	$1.8B	↑ 1.08%
Net Income	$2.3B	↑ 70.46%
Net Profit Margin	129.45%	↑ 52.69%

	FY20	Y/Y Change
Revenue	$2.1B	↑ 16.96%
Net Income	$495.2M	↓ 78.91%
Net Profit Margin	23.34%	↓ 106.11%

	FY21	Y/Y Change
Revenue	$2.3B	↑ 7.89%
Net Income	$478.8M	↓ 3.32%
Net Profit Margin	20.91%	↓ 2.43%

	FY22	Y/Y Change
Revenue	$2.2B	↓ 2.28%
Net Income	$42.8M	↓ 91.05%
Net Profit Margin	1.91%	↓ 19.0%

	FY23	Y/Y Change
Revenue	$2.4B	↑ 5.24%
Net Income	$1.1B	↑ 2549.5%
Net Profit Margin	48.2%	↑ 46.29%

	Q2 FY23	Q/Q Change
Revenue	$538.2M	↓ 21.31%
Net Income	$227.6M	↓ 33.2%
Net Profit Margin	42.29%	↓ 7.53%

	Q3 FY23	Q/Q Change
Revenue	$536.3M	↓ 0.35%
Net Income	$72.1M	↓ 68.32%
Net Profit Margin	13.45%	↓ 28.84%

	Q4 FY23	Q/Q Change
Revenue	$596.0M	↑ 11.13%
Net Income	$494.3M	↑ 585.5%
Net Profit Margin	82.94%	↑ 69.49%

	Q1 FY24	Q/Q Change
Revenue	$568.0M	↓ 4.7%
Net Income	$4.8M	↓ 99.03%
Net Profit Margin	0.84%	↓ 82.1%

	Q2 FY24	Q/Q Change
Revenue	$537.3M	↓ 5.41%
Net Income	$102.0M	↑ 2034.87%
Net Profit Margin	18.99%	↑ 18.15%

	Q3 FY24	Q/Q Change
Revenue	$564.7M	↑ 5.1%
Net Income	$544.0M	↑ 433.3%
Net Profit Margin	96.33%	↑ 77.34%

	FY18	Y/Y Change
Total Assets	$11.4B	-
Total Liabilities	$6.8B	-

	FY19	Y/Y Change
Total Assets	$12.4B	↑ 9.5%
Total Liabilities	$6.3B	↓ 7.47%

	FY20	Y/Y Change
Total Assets	$21.1B	↑ 69.46%
Total Liabilities	$6.1B	↓ 2.92%

	FY21	Y/Y Change
Total Assets	$17.5B	↓ 16.97%
Total Liabilities	$7.3B	↑ 18.67%

	FY22	Y/Y Change
Total Assets	$16.8B	↓ 4.01%
Total Liabilities	$7.3B	↑ 0.29%

	FY23	Y/Y Change
Total Assets	$16.4B	↓ 2.57%
Total Liabilities	$6.3B	↓ 13.59%

	Q2 FY23	Q/Q Change
Total Assets	$17.1B	↑ 0.28%
Total Liabilities	$7.3B	↑ 0.77%

	Q3 FY23	Q/Q Change
Total Assets	$15.9B	↓ 7.39%
Total Liabilities	$6.3B	↓ 14.2%

	Q4 FY23	Q/Q Change
Total Assets	$16.4B	↑ 3.32%
Total Liabilities	$6.3B	↑ 0.43%

	Q1 FY24	Q/Q Change
Total Assets	$16.1B	↓ 1.53%
Total Liabilities	$6.3B	↓ 0.48%

	Q2 FY24	Q/Q Change
Total Assets	$17.7B	↑ 9.46%
Total Liabilities	$7.9B	↑ 26.13%

	Q3 FY24	Q/Q Change
Total Assets	$18.0B	↑ 2.18%
Total Liabilities	$7.8B	↓ 1.53%

	FY18	Y/Y Change
Operating Cash Flow	$1.6B	↑ 14.1%
Investing Cash Flow	$303.4M	↓ 119.11%
Financing Cash Flow	$-1.4B	↑ 1018.91%

	FY19	Y/Y Change
Operating Cash Flow	$1.7B	↑ 3.02%
Investing Cash Flow	$-2.2B	↓ 809.77%
Financing Cash Flow	$-1.2B	↓ 13.59%

	FY20	Y/Y Change
Operating Cash Flow	$2.0B	↑ 22.04%
Investing Cash Flow	$-2.8B	↑ 28.12%
Financing Cash Flow	$1.5B	↓ 224.79%

	FY21	Y/Y Change
Operating Cash Flow	$2.0B	↓ 0.84%
Investing Cash Flow	$-1.9B	↓ 32.22%
Financing Cash Flow	$385.1M	↓ 74.1%

	FY22	Y/Y Change
Operating Cash Flow	$2.1B	↑ 6.27%
Investing Cash Flow	$-1.0B	↓ 44.96%
Financing Cash Flow	$-944.9M	↓ 345.35%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$607.8M	↓ 41.21%
Investing Cash Flow	$-63.4M	↓ 88.64%
Financing Cash Flow	$-347.0M	↑ 64.94%

Royalty Pharma Plc Technicals Summary

Sell

Neutral

Buy

Royalty Pharma Plc is currently in a neutral trading position according to technical analysis indicators.

Royalty Pharma Plc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Royalty Pharma Plc	-1.99%	-0.67%	-5.86%	-29.19%	-40.09%
Regeneron Pharmaceuticals, Inc.	-9.49%	-24.18%	-8.88%	18.12%	102.78%
Biontech Se	8.64%	15.09%	18.5%	-65.59%	454.0%
Alnylam Pharmaceuticals, Inc.	-6.25%	68.21%	46.39%	47.68%	107.47%
Vertex Pharmaceuticals Incorporated	-0.99%	-0.44%	33.51%	129.69%	109.07%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Royalty Pharma Plc	10.47	10.47	5.77	3.97	0.17	0.06	0.03	15.4
Regeneron Pharmaceuticals, Inc.	18.66	18.66	1.12	44.91	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.22	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Royalty Pharma Plc	Buy	$15.7B	-40.09%	10.47	50.53%
Regeneron Pharmaceuticals, Inc.	Buy	$83.0B	102.78%	18.66	33.61%
Biontech Se	Buy	$28.9B	454.0%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	107.47%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$119.6B	109.07%	32.84	-4.51%

Royalty Pharma Plc Dividend announcements

Royalty Pharma Plc Dividends June, 2024
In the quarter ending June,2024. Royalty Pharma Plc has declared dividend of $0.21
Read More

About Royalty Pharma Plc

royalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products. royalty pharma’s strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies. royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott’s humira®, j&j/merck’s remi

Organization	Royalty Pharma Plc
Employees	0
CEO	Mr. Pablo Gerardo Legorreta
Industry	Health Technology

Important FAQs about investing in Royalty Pharma Plc from India :

What is Royalty Pharma Plc share price today?

Royalty Pharma Plc (RPRX) share price today is $26.66.

Can Indians buy Royalty Pharma Plc shares?

Yes, Indians can invest in the Royalty Pharma Plc (RPRX) from India.

With INDmoney, you can buy Royalty Pharma Plc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Royalty Pharma Plc at zero transaction cost.

How can I buy Royalty Pharma Plc shares from India?

It is very easy to buy Royalty Pharma Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Royalty Pharma Plc be purchased?

Yes, you can buy fractional shares of Royalty Pharma Plc with INDmoney app.

What are the documents required to start investing in Royalty Pharma Plc stocks?

To start investing in Royalty Pharma Plc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.